EGFR and head and neck squamous cell carcinoma: Interestingly, this identified epidermal growth factor receptor (EGFR) as a prominent target, although recently failed trials using cetuximab have cast doubt over EGFR targeting as a therapeutic strategy in HNSCC [34,35].